Progress in clinic diagnosis of sera aquaporin-4 antibody negative neuromyelitis optica
10.11958/20170132
- VernacularTitle:水通道蛋白4抗体阴性视神经脊髓炎的临床诊断进展
- Author:
Ningnannan ZHANG
;
Zhang ZHANG
- Keywords:
neuromyelitis optica;
aquaporin 4;
aquaporin 4 antibody;
functional imaging;
review
- From:
Tianjin Medical Journal
2017;45(5):548-552
- CountryChina
- Language:Chinese
-
Abstract:
According to the sera aquaporin-4 antibody (AQP4), neuromyelitis optica (NMO) can be classified into two types as AQP4 antibody positive (AQP4+) and negative (AQP4-). However, the NMO patients with AQP4- are prone to delayed treatment, and may have a different pathogenesis compared to that in patients with AQP4+. Scientific researches and the clinical trials on NMO with AQP4- will deepen the understanding of NMO pathogenesis and help to make an early accurate diagnosis and rational therapy for NMO with AQP4-. This review aims to summarize the progress in clinic diagnosis for NMO patients with AQP4-.
